TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
about
Biology of RANK, RANKL, and osteoprotegerinTTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activationMIP-T3, a novel protein linking tumor necrosis factor receptor-associated factor 3 to the microtubule networkT6BP, a TRAF6-interacting protein involved in IL-1 signalingCIKS, a connection to Ikappa B kinase and stress-activated protein kinaseCSN3 interacts with IKKgamma and inhibits TNF- but not IL-1-induced NF-kappaB activationA novel zinc finger protein that inhibits osteoclastogenesis and the function of tumor necrosis factor receptor-associated factor 6Structure and functional properties of the ubiquitin binding protein p62Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signalingThe LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complexRBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradationInterleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosolRole of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesisDissection of a signaling pathway by which pathogen-associated molecular patterns recruit the JNK and p38 MAPKs and trigger cytokine releaseSphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast couplingSite-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activationEssential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signalingTAB3, a new binding partner of the protein kinase TAK1TRAF6-deficient mice display hypohidrotic ectodermal dysplasia.Impaired neural tube closure, axial skeleton malformations, and tracheal ring disruption in TRAF4-deficient mice.Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cellsReceptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6Stress-induced decrease in TRAF2 stability is mediated by Siah2MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signalingInterleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathwaymiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in miceRANK is essential for osteoclast and lymph node developmentMKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokinesDeficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcriptionThe atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathwayRole of the TAB2-related protein TAB3 in IL-1 and TNF signalingIL-1-induced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK)Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activationTumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclastsThe RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKLOsteoimmunology: interactions of the bone and immune systemMolecular basis for CD40 signaling mediated by TRAF3Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinaseMolecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signalingRequirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction
P2860
Q21195419-7D03432B-2AF5-44BD-8FD4-B7A363AB7FBAQ22253885-866DD23D-E20C-43CC-90FB-6B93F6A6D3DDQ22254016-174DC6C8-3F90-480B-B82D-BB482C148A4DQ22254711-091DC69D-AE46-4847-A12C-95D57D677BCFQ24290148-9D87A8DA-58A3-4092-8E2B-792C9F8B3EA5Q24291350-F9356A40-FF07-4444-AB87-AA46C5A6DAADQ24292059-2DE8D28F-8F0C-4A11-B1D9-B789E2968A34Q24292324-2F86BE7A-F691-4537-AB49-D7F642CDD895Q24299892-CC8506EF-C26C-4B4B-9363-A84073E85610Q24301337-1D17A44A-0D51-4867-8E1B-85142622C857Q24303616-CB05828B-3F57-4640-B174-0A8F111C84EEQ24307324-42AEE33B-9AC3-4DCC-9129-B7ACE4A2B0D1Q24311417-B0A11F54-BA92-4073-BE6D-6F93F3B414EAQ24312954-678C8230-AA1B-4FDC-9650-C1B25D15B55CQ24319108-18956E59-51D7-4C5D-9E15-119F5128B5ABQ24321363-E1F0BABB-2572-42F9-8C7B-FB4EA1339E33Q24337661-381B9300-9020-4DFC-A398-E63E3875D0FAQ24530663-CC46FC52-0862-489B-9C3E-23BBAAF5309CQ24530773-1F60FBD6-07C6-4409-BC1E-04E270920C13Q24534150-530EBFD3-FB2C-4A73-8FD3-45DCF250039AQ24534892-978F329A-5649-4A45-8067-7E30F73011BFQ24537518-0A5ADAA6-6C46-4358-9B06-25D993ED779FQ24539054-EB7413B9-4773-4616-8CDA-61E48BBF7359Q24548375-ACDCA186-4C22-43E9-AC40-646D4E0E03D9Q24550984-1A6368BE-A63B-4680-8EFB-2191D86D1CDDQ24595073-CE25A03B-6F3F-453E-92F9-131E6A1779CDQ24598872-4A62411B-3807-4AF5-BA8F-9FB77278DC0AQ24601753-E982179B-21A8-48DE-A878-FD1E11DCC16AQ24630171-F9F8C18E-C401-40EE-8B05-CC67F1F8A4B4Q24630760-14104BF2-C08E-4FC5-A813-EB35F1470302Q24633992-83055483-F7A8-4308-BFD0-41CC3B1D8627Q24635274-4F940CC8-F8F4-4A3B-B1A3-30B35AD48EFFQ24641992-AB2E86D5-669D-4A81-8165-12552AAC22E0Q24651323-3512515F-2954-4096-9F33-E790E145F736Q24654977-BB045928-5A40-48DF-BC71-8527BF6C442DQ24655113-D089D94E-0C0C-4799-B468-8FC58466B878Q24656208-E4794D76-6B7C-479E-857A-9D56F3002C8BQ24658087-A1507091-E2BB-4FF1-9D55-18FA6B5063A6Q24675633-4D9E039E-0F37-4C6A-94C9-8AA2FA758F0EQ24676400-DE6F6352-1046-4553-8CAE-30BA49A31A92
P2860
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
description
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1999
@ast
im April 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/04/15)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/04/15)
@nl
наукова стаття, опублікована у квітні 1999
@uk
مقالة علمية (نشرت في 15-4-1999)
@ar
name
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@ast
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@en
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@nl
type
label
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@ast
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@en
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@nl
prefLabel
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@ast
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@en
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@nl
P2093
P2860
P3181
P356
P1433
P1476
TRAF6 deficiency results in os ...... kin-1, CD40, and LPS signaling
@en
P2093
A van der Heiden
C Capparelli
C Furlonger
D V Goeddel
G S Duncan
P2860
P304
P3181
P356
10.1101/GAD.13.8.1015
P577
1999-04-01T00:00:00Z